Machova Polakova, Katerina http://orcid.org/0000-0002-7398-5555
Zizkova, Hana
Zuna, Jan
Motlova, Eliska
Hovorkova, Lenka
Gottschalk, Andrea
Glauche, Ingmar http://orcid.org/0000-0002-2524-1199
Koblihova, Jitka
Pecherkova, Pavla
Klamova, Hana
Stastna Markova, Marketa
Srbova, Dana
Benesova, Adela
Polivkova, Vaclava
Jurcek, Tomas
Zackova, Daniela
Mayer, Jiri
Ernst, Thomas
Mahon, Francois X.
Saussele, Susanne
Roeder, Ingo http://orcid.org/0000-0002-6741-0608
Cross, Nicholas C. P. http://orcid.org/0000-0001-5481-2555
Hochhaus, Andreas
Funding for this research was provided by:
Agentura Pro Zdravotnický Výzkum České Republiky (15-31540A, 16-31540A, 15-31540A, 15-31540A)
Ministerstvo Zdravotnictví Ceské Republiky (00023736, 00064203)
European Treatment and Outcome study (EUTOS) for CML
European Treatment and Outcome Study (EUTOS) for CML
ERA-Net ERACoSysMed JTC-2 project “prediCt”
Article History
Received: 6 January 2020
Revised: 14 May 2020
Accepted: 19 May 2020
First Online: 29 May 2020
Compliance with ethical standards
:
: KMP, TE, NCPC and AH received support by Novartis through the European Treatment and Outcome Study (EUTOS) for CML. The authors declare that they have no conflict of interest.
: This work was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committees of the Institute of Hematology and Blood Transfusion, Prague and Faculty Hospital Brno.
: All patients provided written informed consent for the use of their samples for this research.